TNBC is notoriously difficult to detect and treat due to its significant heterogeneity. Unlike breast cancers driven primarily by hormone receptors or HER2 expression, TNBC encompasses a complex array of molecular subtypes, each with distinct characteristics and clinical outcomes. This diversity complicates the development of universal diagnostic markers and targeted therapies. Noninvasive imaging techniques capable of accurately identifying and characterizing the wide spectrum of TNBC tumors remain elusive, severely limiting precision medicine approaches for these patients.

In response to this challenge, a team led by experts at Memorial Sloan Kettering Cancer Center devised an innovative strategy centered on the tumor microenvironment rather than tumor cell markers alone. They focused on extra domain A of fibronectin (EDA-FN), a splice variant of the fibronectin protein abundantly and stably expressed within the extracellular matrix of many aggressive tumors, including TNBC. The consistent presence of EDA-FN in the tumor stroma across diverse subtypes makes it an attractive target to circumvent the heterogeneity that stymies conventional markers.

The researchers engineered a monoclonal antibody-based radiotracer, designated [^89Zr]Zr-DFO-F8, designed to selectively bind EDA-FN. By labeling this antibody with Zirconium-89, a positron-emitting isotope suitable for PET imaging, the team created a tracer capable of delivering high-resolution, quantitative images of EDA-FN distribution in vivo. This molecular imaging agent was rigorously evaluated through a series of in vitro assays and preclinical in vivo models that represent multiple TNBC subtypes, assessing its specificity, binding affinity, and tumor uptake.

In vitro studies confirmed the high specificity and blockable binding of [^89Zr]Zr-DFO-F8 to EDA-FN, demonstrating that the tracer interacts precisely with its intended target without significant off-target effects. Subsequently, in vivo experiments utilizing various xenograft models implanted subcutaneously and orthotopically within murine hosts revealed robust accumulation of the tracer within tumors expressing elevated levels of EDA-FN. Notably, tracer uptake correlated strongly with the degree of EDA-FN expression and tumor aggressiveness, underscoring its utility as a marker of malignant potential.

This imaging modality transcends traditional tumor cell–centric approaches by exploiting the tumor’s extracellular matrix, thereby bypassing the variability of surface markers inherent to tumor cells themselves. The results herald a paradigm shift in the nuclear medicine field, positioning extracellular matrix components as reliable, broadly applicable targets for cancer imaging. Consequently, [^89Zr]Zr-DFO-F8 has the potential not only to detect TNBC earlier and more accurately but also to guide precision therapy by identifying patients who might benefit from stromal-targeted treatments or monitoring therapeutic efficacy dynamically.

“This approach represents a significant stride toward overcoming the tumor heterogeneity that has impeded effective imaging in triple-negative breast cancer,” remarked Dr. Jason Lewis, the study’s senior investigator. “By focusing on a stable, abundant extracellular protein like EDA-FN, we open avenues for more universal diagnostic tools that can address the diversity and complexity of TNBC,” Lewis explained. The tracer’s ability to visualize tumor microenvironment components rather than relying solely on tumor cells broadens the applicability of such imaging agents across a spectrum of hard-to-target cancers.

Beyond diagnostic applications, the [^89Zr]Zr-DFO-F8 tracer may facilitate personalized treatment planning. Imaging results can inform clinicians about tumor invasiveness and stromal composition, essential parameters that influence therapeutic responses. By enabling longitudinal monitoring of tumor microenvironment alterations during treatment, this imaging technique provides a noninvasive means to evaluate effectiveness and adapt regimens in real time, arguably enhancing patient outcomes and fostering more rationalized clinical decisions.

The research team employed several preclinical TNBC models to comprehensively validate their tracer. These models encompassed diverse molecular profiles, ensuring that the imaging agent’s utility would not be limited to a narrow subset of TNBC. Remarkably, EDA-FN targeting by [^89Zr]Zr-DFO-F8 succeeded across all tested models, highlighting the robust and ubiquitous nature of this extracellular matrix marker. Such broad-spectrum applicability is a critical feature enabling this technology to have widespread clinical influence.

While many current molecular imaging probes target tumor-specific receptors or antigens, issues with variable expression and rapid mutation limit their long-term clinical utility, particularly in heterogeneous diseases like TNBC. [^89Zr]Zr-DFO-F8 circumvents these challenges by homing in on stromal proteins that are less prone to genetic alterations and provide a stable target environment. This strategy aligns with the evolving appreciation of the tumor microenvironment’s role in cancer progression and resistance, offering new vistas for theranostic development.

Looking ahead, ongoing work aims to translate these promising findings into human clinical trials. Critical questions remain regarding tracer pharmacokinetics, dosimetry, safety profiles, and imaging protocols. Nevertheless, the preclinical data position [^89Zr]Zr-DFO-F8 as a frontrunner in the quest for universal TNBC imaging agents. The successful clinical implementation of this technology could substantially improve the landscape for one of the most difficult breast cancer subtypes, ultimately enhancing survival and quality of life for patients worldwide.

This research exemplifies the power of multidisciplinary collaboration, integrating molecular biology, radiochemistry, and nuclear medicine in a concerted effort to address unmet clinical needs. Partnering with industry experts, including those from Philochem AG and Philogen Group, the investigators have leveraged antibody engineering and radiolabeling expertise to develop a state-of-the-art tracer that marries specificity with translational potential. Such synergies highlight how innovation at the intersection of science and technology can accelerate impactful advances in cancer care.

In sum, the development of [^89Zr]Zr-DFO-F8 as a PET imaging agent targeting the extracellular matrix protein EDA-FN heralds a new era in triple-negative breast cancer detection and management. By sidestepping the limitations imposed by tumor heterogeneity and focusing on the tumor microenvironment, this approach provides a compelling pathway to improved diagnosis, treatment planning, and monitoring. As the fight against TNBC intensifies, molecular imaging innovations like this offer hope for more effective, personalized interventions that can ultimately save lives.

Subject of Research: Targeting Extra Domain A of Fibronectin for molecular imaging of triple-negative breast cancer

Article Title: Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer

News Publication Date: June 4, 2025

Web References:

• Journal of Nuclear Medicine Article
• JNM Website
• Journal of Nuclear Medicine Twitter
• Journal of Nuclear Medicine Facebook
• Journal of Nuclear Medicine LinkedIn

Image Credits: Images created by Justin S. Hachey, Memorial Sloan Kettering Cancer Center, New York, NY.

Keywords: Molecular imaging, breast cancer, triple-negative breast cancer, positron emission tomography, extracellular matrix, fibronectin, tumor heterogeneity, PET tracer, EDA-FN, zirconium-89, monoclonal antibody, tumor microenvironment

Breast cancer classification traditionally hinges on immunohistochemical assessments of tissue biopsies to determine molecular subtypes. These subtypes—luminal A, luminal B, HER2-overexpressing (HER2), and triple-negative breast cancer (TNBC)—have distinct prognostic and therapeutic implications. However, biopsy procedures can be invasive, time-consuming, and sometimes limited by tumor heterogeneity or sampling errors. Therefore, developing reliable imaging-based prediction tools could significantly enhance early diagnosis and individualized treatment planning.

Multimodal ultrasound imaging has emerged as a powerful, radiation-free diagnostic modality capable of capturing diverse tissue characteristics. Conventional ultrasound (CUS) provides morphological information such as lesion size, shape, and echogenicity. Shear wave elastography (SWE) quantifies tissue stiffness, reflecting biomechanical changes associated with malignancy. Contrast-enhanced ultrasound (CEUS) assesses tumor vascularity and perfusion patterns, offering insights into angiogenic activity. The integration of these imaging techniques captures a holistic view of tumor biology, potentially correlating imaging phenotypes with molecular subtypes.

In this comprehensive study, breast cancer patients who underwent CUS, SWE, and CEUS imaging from January 2023 to June 2024 were meticulously analyzed. Researchers selected pertinent clinical and imaging parameters that revealed statistically significant variations among breast cancer molecular subtypes. Ten critical features emerged, including BI-RADS categorization, presence of palpable mass, tumor aspect ratio, maximum diameter, calcification status, heterogeneous echogenicity, irregular lesion shape, the standard deviation of the elastic modulus within lesions, and CEUS parameters such as arrival time and peak intensity.

Building on these findings, the research team developed multiple binary prediction models targeting each molecular subtype independently. The models were constructed from several feature sets: CUS features alone, SWE features alone, CEUS features alone, and a comprehensive full-parameter feature set that amalgamated data across all imaging modalities alongside clinical information. This stratified modeling approach allowed for a nuanced comparison of the predictive power contributed by each modality.

The results underscored the superior performance of models utilizing full multimodal parameter integration. Each prediction model demonstrated higher accuracy and robustness when all imaging and clinical variables were considered collectively, compared to models limited to single-modal features. Specifically, the area under the receiver operating characteristic curves (AUCs) for the full parameter models were 0.81 for luminal A, 0.74 for luminal B, 0.89 for HER2-overexpressing, and 0.78 for triple-negative breast cancer. These metrics reflect strong discriminative ability, essential for clinical decision-making.

Importantly, these findings affirm that molecular heterogeneity in breast cancer manifests as distinct imaging phenotypes detectable via advanced ultrasound techniques. Features such as tissue stiffness variability and contrast enhancement patterns appear intimately linked to underlying tumor biology, including cellular proliferation rates, hormone receptor expression, and vascular architecture. This concordance between imaging biomarkers and molecular subtypes opens new avenues for non-invasive tumor characterization.

From a clinical perspective, these prediction models have notable implications. Accurate preoperative identification of molecular subtype can guide therapeutic choices—ranging from endocrine therapy suitability for luminal cancers to targeted HER2-directed therapies or chemotherapy regimens tailored for triple-negative tumors. Moreover, non-invasive imaging could facilitate serial monitoring of tumor evolution or response to therapy without repeated biopsies.

The adoption of multimodal ultrasound in standard clinical workflows also offers logistical and economic benefits. Ultrasound devices are widely accessible, cost-effective, and do not expose patients to ionizing radiation, making them particularly suitable for frequent monitoring and application in resource-constrained settings. These advantages bolster the feasibility of personalized management strategies informed by imaging-based molecular classification.

Technically, the study employed rigorous statistical analyses to identify discriminative features, incorporating machine learning algorithms to optimize prediction model performance. Binary classifiers for each subtype were carefully validated using test data sets to ensure generalizability and minimize overfitting. Evaluation metrics extended beyond AUCs to include accuracy, precision, recall, and F1 scores, providing a comprehensive assessment of model reliability.

Notably, the integration of SWE parameters—such as the standard deviation of the lesion’s elastic modulus—highlighted the importance of tumor biomechanical heterogeneity in differentiating subtypes. Tumors exhibiting increased stiffness variability tend to correlate with aggressive phenotypes like HER2-overexpressing and triple-negative cancers. Similarly, CEUS-derived parameters reflecting microvascular flow dynamics enriched the predictive capacity by correlating with angiogenic profiles associated with specific molecular subtypes.

While these findings are promising, the researchers acknowledge the need for further validation in larger, multi-center cohorts to consolidate the clinical utility of the proposed models. Expanding the feature set to include emerging ultrasound modalities and advanced image analysis techniques, such as radiomics and deep learning, may further enhance predictive accuracy. Additionally, integration with other non-invasive biomarkers like circulating tumor DNA could create synergistic diagnostic frameworks.

In conclusion, this pioneering study marks a significant leap toward non-invasive, precision-guided management of breast cancer. By harnessing the complementary strengths of multimodal ultrasound and clinical features, clinicians are now closer to accurately predicting molecular subtypes preoperatively, facilitating tailored therapeutic interventions. This approach has the potential to improve patient outcomes, reduce unnecessary treatments, and optimize healthcare resources.

As breast cancer heterogeneity continues to challenge oncologists worldwide, such technological innovations exemplify how advanced imaging and data science converge to transform cancer care. The capability to decode molecular signatures through ultrasound imaging underscores a new frontier in personalized medicine—one where treatment strategies are as dynamic and multifaceted as the tumors themselves.

The promising results from this research herald a future where ultrasound-guided precision oncology becomes routine, empowering clinicians with rapid, reliable, and non-invasive tools to unravel the complex biological landscape of breast cancer at the patient’s bedside.

Subject of Research: Prediction of breast cancer molecular subtypes using multimodal ultrasound imaging and clinical features.

Article Title: Prediction models of breast cancer molecular subtypes based on multimodal ultrasound and clinical features.

Article References:
Li, H., Zhang, Ct., Shao, Hg. et al. Prediction models of breast cancer molecular subtypes based on multimodal ultrasound and clinical features. BMC Cancer 25, 886 (2025). https://doi.org/10.1186/s12885-025-14233-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14233-6

Triple-negative breast cancer, a subtype of breast cancer that accounts for approximately 15-20% of cases, is known for its highly invasive characteristics. With existing treatment options often falling short and a disheartening five-year survival rate hovering around 40%, significant advancements in diagnostic methodologies are essential. TNBC is a heterogeneous disease, frequently marked by high rates of recurrence. As such, the quest for effective biomarker-driven imaging tools has never been more urgent. The emergence of Nectin-4 as a promising biomarker may represent a pivotal step forward.

Researchers led by Shaoli Song, PhD, who serves as the director of nuclear medicine at the Fudan University Shanghai Cancer Center, have dedicated their efforts to address a critical gap in TNBC diagnosis. Dr. Song and her colleagues recognized that although Nectin-4 is significantly overexpressed in TNBC tissues, the absence of efficient imaging modalities has hindered its clinical applicability. Thus, the idea to develop targeted radiotracers that could bind to Nectin-4 was born, leading to the creation of a series of agents including 68Ga-FZ-NR-1, 68Ga-FZ-NR-2, and 68Ga-FZ-NR-3.

In their comprehensive studies, the research team meticulously evaluated the efficacy of these radiotracers through a series of rigorous preclinical experiments, both in vitro and in vivo. These investigations included a murine tumor model, where the targeting abilities and specificity of each radiotracer were analyzed. Ultimately, 68Ga-FZ-NR-1 emerged as the frontrunner, demonstrating superior targeting efficacy against Nectin-4. Encouraged by these promising results, the researchers proceeded to embark on a first-in-human study involving nine TNBC patients.

The application of 68Ga-FZ-NR-1 PET/CT imaging in these patients yielded remarkable outcomes, enabling the identification of tumors that were corroborated by conventional imaging techniques such as 18F-FDG PET/CT. This validation process underscored the accuracy of the novel radiotracer in pinpointing areas with elevated Nectin-4 expression. By comparing the findings from PET imaging with biopsy samples taken from the identified lesions, researchers could confirm the correlation between the radiotracer’s detection capabilities and the actual expression levels of the biomarker, thus reinforcing the scientific foundation of this innovative approach.

Dr. Song expressed the significance of this research in revolutionizing the diagnostic landscape for TNBC patients. With the advent of 68Ga-FZ-NR-1, the potential for achieving higher precision in tumor detection has opened doors to more reliable diagnostic information. This progress could lead to improvements in treatment outcomes through more accurate disease assessment and tailored therapeutic strategies, highlighting the importance of personalized medicine in oncology.

The implications of 68Ga-FZ-NR-1 extend beyond TNBC alone. The researchers anticipate that their findings will inspire further investigation into Nectin-4-targeted imaging agents, potentially enhancing the diagnostic efficacy of nuclear medicine not just for TNBC, but for a broader spectrum of malignancies as well. The hope is that this trajectory may lead to the development of new imaging tools that can assist in the management of various cancers characterized by heterogeneity and complex treatment responses.

As the medical community eagerly awaits the subsequent phases of research, the introduction of an innovative biomarker such as Nectin-4 represents a hopeful turning point in the ongoing battle against cancer. Such advancements remind us of the pressing need for continued research and innovation within the field of molecular imaging and nuclear medicine. The endeavor undertaken by Dr. Song and her collaborators reinforces the commitment to tackling the major challenges posed by aggressive cancers, ultimately aiming to enhance survival rates and the quality of life for patients worldwide.

Their pioneering work not only illuminates the path for future studies but also establishes a foundation on which new therapeutic initiatives can be built. As we move into an era where precision medicine becomes increasingly central to cancer treatment, developments like 68Ga-FZ-NR-1 symbolize the crucial intersection of research and clinical application, fostering hope for better diagnostic and therapeutic outcomes.

In conclusion, the advancement of 68Ga-FZ-NR-1 as a targeted imaging agent for Nectin-4 in TNBC represents a significant stride toward bridging the gaps in cancer diagnosis and treatment. With its potential to revolutionize personalized medicine strategies, this groundbreaking research encourages the scientific community to persist in exploring innovative solutions to the multifaceted challenges cancer poses. As research continues to unfold, collaboration and ingenuity will be essential to changing the narrative of cancer treatment and improving patient care in the years to come.

Subject of Research: Nectin-4-targeted PET imaging in triple-negative breast cancer
Article Title: Pilot Study of Nectin-4–Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human
News Publication Date: March 1, 2025
Web References: Journal of Nuclear Medicine
References: DOI
Image Credits: Created by Dr. Li Sun and Dr. Xiaoping Xu, Shanghai Cancer Center
Keywords: Molecular imaging, Breast cancer, Positron emission tomography